CPT code 47371 denotes laparoscopic cryosurgical ablation of one or more liver tumors. The code captures a minimally invasive, laparoscopy-based cryoablation technique used to destroy hepatic tumor tissue. This procedure is clinically significant as a liver-directed treatment option for select patients with primary or metastatic hepatic tumors, offering a potentially organ-preserving alternative to open resection.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, common service settings, and payer coverage considerations. The publication outlines national benchmarks for utilization and reimbursement patterns, summarizes relevant policy and coverage updates affecting ablation services, and clarifies coding and billing considerations related to procedural reporting for laparoscopic cryoablation.

Intended for clinicians, coding professionals, and policy analysts, the report provides actionable reference material on where CPT code 47371 fits within liver-directed therapies, how payers commonly approach coverage, and what documentation elements are typically relevant for claims processing. Data not available in the input are explicitly noted where applicable.